![Page Background](./../common/page-substrates/page0014.jpg)
ESC 2017: Catheter Ablation Improves Outcomes in Patients
With Heart Failure and Atrial Fibrillation – CASTLE-AF Trial
Catheter ablation may improve outcomes for patients with left ventricular dysfunction and atrial fibrillation. Patients
who received catheter ablation of atrial fibrillation had lower mortality and less hospitalization for worsening heart
failure than those receiving conventional drug treatment.
T
his outcome of Catheter Ablation vs
Standard conventional Treatment
in patients with LV dysfunction and
AF (CASTLE-AF) was reported at the 2017
European Society of Cardiology (ESC) Con-
gress, from August 26–30.
“The medical community continues to
debate the ideal treatment for atrial fibril-
lation in patients with left ventricular
dysfunction because clinical studies that
support one definitive treatment are lack-
ing. Common therapies for atrial fibrillation
include medication that regulates or slows
the heart rate,” said Nassir F. Marrouche,
MD, of the Comprehensive Arrhythmia
Research and Management (CARMA) Cen-
tre, University of Utah Health, Salt Lake City
Dr. Marrouche and Johannes Brachmann,
MD, of the Klinikum Coburg, Germany,
jointly conducted a clinical trial to exam-
ine the effect of catheter ablation on
all-cause mortality and hospitalization rates
in patients with atrial fibrillation and left
ventricular dysfunction, vs state-of-the art
conventional treatment recommended by
the American Heart Association and Euro-
pean Society of Cardiology.
CASTLE-AF is the first randomized clini-
cal trial comparing catheter ablation to
current first-line antiarrhythmic drug ther-
apy for patients with coexisting heart
failure (HF) and atrial fibrillation evaluat-
ing the primary outcome of mortality and
hospitalization for worsening heart failure.
After screening more than 3000 patients,
CASTLE-AF included 397 patients with
symptomatic paroxysmal or persistent atrial
fibrillation and heart failure with ejection
fraction <35%.
All patients were supplied with an implant-
able cardioverter defibrillator with home
monitoring capability to enable continuous
surveillance of atrial fibrillation. Patients were
recruited from more than 30 clinical centers
from North America, Europe, and Australia.
Patientswere randomized to radiofrequency
catheter ablation or conventional drug
COMMENT
By Clyde W Yancy
MD, MSc, MACC, FAHA, MACP, FHFSA
CASTLE-AF
“Catheter ablation versus standard con-
ventional treatment in patients with left
ventricular dysfunction and atrial fibril-
lation: the CASTLE-AF trial,” a study of
397 patients, evaluated the benefit of
catheter ablation of atrial fibrillation on
hard cardiovascular outcomes in the set-
ting of concomitant heart failure. Over
3000 patients from 30 countries were
screened for participation. All had an
ICD in place with home-monitoring func-
tionality. Patients were randomized to
ablation versus conventional therapy,
either rate or rhythm control. Follow-up
was 37.8 months. The primary endpoint
was all-cause mortality and heart failure
hospitalization. The study was positive,
with a 38% (HR, 0.62; 95% CI, 0.43–0.87;
P = .007) relative risk reduction in the
primary endpoint. The secondary end-
point of death alone demonstrated a 47%
reduction.
These are remarkable results that
are applauded but do raise important
questions:
•
Who were these patients? The large
number screened versus those
enrolled does raise the question of a
selection bias.
•
How was heart failure treated? The
mortality seen in the conventional
therapy arm would suggest more
advanced heart failure. Over the course
of this study, the management of heart
failure has changed.
•
How was medical therapy modified
over the trial, and were the adjustments
in medical therapy similar in both arms?
•
What were the power estimates for the
primary endpoint? Could this be a play
of chance?
Nevertheless, we should take away that
atrial fibrillation ablation in those with
heart failure is a consideration, but the
target patient population and the exact
magnitude of the treatment effect need
refinement. This could be a new direction
of care.
Dr Yancy is Chief of
Cardiology at
Northwestern University,
Feinberg School of
Medicine, Associate
Director of the Bluhm
Cardiovascular Institute at
Northwestern Memorial
Hospital, Magerstadt Endowed Professor of
Medicine Chair, Professor of Medical Social
Sciences, Vice-Dean of Diversity & Inclusion,
Northwestern University, Feinberg School of
Medicine, Chicago, Illinois.
© ESC Congress 2017 – European Society of Cardiology
CONFERENCE COVERAGE
14
PRACTICEUPDATE CARDIOLOGY